High ferritin is a clue; high transferrin saturation reveals an open iron gate.
Reference image for orientation, not a diagnostic studyHigh ferritin is a clue; high transferrin saturation reveals an open iron gate.National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health / NIDDK, NIH (Public domain). SourcePublic domain
Explain how impaired hepcidin signaling increases ferroportin-mediated iron entry into plasma.
Interpret transferrin saturation and ferritin with MRI, genetics, and biopsy in the correct clinical context.
Select phlebotomy for appropriate hereditary overload, chelation for transfusional overload, and HCC surveillance for advanced fibrosis or cirrhosis.
Bilirubin route
Follow the pigment without skipping a compartment
The route distinguishes production, transport, conjugation, excretion, and downstream clues.
Quick check
A 52-year-old man has fatigue, second and third MCP arthropathy, diabetes, bronze skin, transferrin saturation of 68 percent, and ferritin of 920 micrograms/L. HFE testing shows C282Y homozygosity.
Which treatment best removes the excess iron?
Reason it through
Do the iron studies show circulating iron excess?Yes; transferrin saturation is markedly elevated.
Is there established organ involvement?Yes; joints, pancreas, and skin are affected.
Can the patient tolerate red-cell removal?No anemia or other contraindication is described, so phlebotomy is appropriate.
HFE overload with usable hemoglobin is a phlebotomy problem.
Separate hereditary loading from transfusional loading
Iron can enter plasma through an open ferroportin gate or arrive inside donor red cells.
Classic HFE hemochromatosis most often involves C282Y homozygosity and inappropriately low hepcidin signaling, which increases intestinal absorption and macrophage iron release. Penetrance is variable, so genotype alone does not equal organ disease.
Non-HFE hemochromatosis includes HJV, HAMP, TFR2, and selected SLC40A1 disorders, often with younger or atypical presentation. Secondary overload follows repeated transfusion or ineffective erythropoiesis and is treated according to anemia, transfusion burden, and organ iron rather than by assuming an HFE mechanism.
Compare the three loading patterns.
Adult-onset high transferrin saturation with C282Y homozygosity and variable clinical penetrance.
Rare hepcidin-pathway or ferroportin disorders, sometimes severe and early, requiring phenotype-guided multigene evaluation.
Transfusions or ineffective erythropoiesis add iron despite anemia; MRI monitoring and chelation often replace phlebotomy.
Name how iron entered before choosing how to remove it.
Trace hepcidin to parenchymal injury
Hepcidin is the brake and ferroportin is the exit channel.
Hepcidin binds ferroportin on enterocytes and macrophages, causing internalization and reducing iron release into plasma. HFE, HJV, HAMP, and TFR2 participate in sensing or signaling that raises hepcidin when stores are sufficient.
When hepcidin is inappropriately low or ineffective, ferroportin remains active, transferrin becomes highly saturated, non-transferrin-bound iron appears, and parenchymal cells accumulate toxic iron that promotes oxidative injury and fibrosis.
Order the pathogenic sequence.
HFE, transferrin receptors, and hemojuvelin help signal iron sufficiency.
The liver releases the hormone that restrains systemic iron entry.
Hepcidin reduces iron export from enterocytes and macrophages.
Pathway defects leave ferroportin active despite adequate stores.
Excess circulating iron loads liver, pancreas, heart, pituitary, joints, and skin.
Use thresholds as gates to context
Numbers guide the next test, but genotype, inflammation, anemia, and fibrosis decide meaning.
In C282Y homozygotes, EASL accepts transferrin saturation above 45 percent with ferritin above 200 micrograms/L in females, or saturation above 50 percent with ferritin above 300 micrograms/L in males and postmenopausal females, as provisional biochemical overload.
Ferritin above 1,000 micrograms/L increases concern for advanced fibrosis and should prompt staging. Patients with cirrhosis undergo HCC surveillance about every 6 months, commonly with ultrasound and AFP when appropriate.
Rank the findings by urgency for organ staging.
Interpret saturation before worshiping ferritin
Ferritin rises in many illnesses; transferrin saturation better reveals expanded circulating iron.
Ferritin reflects iron stores but is also an acute-phase reactant that rises with inflammation, infection, malignancy, alcohol-associated liver disease, and metabolic liver disease.
Persistent elevation of transferrin saturation raises suspicion for hemochromatosis. EASL uses thresholds above 45 percent in females and above 50 percent in males as part of the diagnostic pathway, paired with ferritin and genotype or direct evidence of hepatic iron.
Select the result that most specifically prompts hereditary iron-loading evaluation.
Choose the first item.
Ferritin is loud; transferrin saturation is directional.
Map iron by organ and imaging compartment
Where iron accumulates determines both symptoms and the best measurement.
Liver iron promotes fibrosis, cirrhosis, and hepatocellular carcinoma risk. Pancreatic and pituitary injury can cause diabetes and hypogonadism, cardiac iron causes arrhythmia or cardiomyopathy, and joint disease often targets the second and third MCP joints.
Validated MRI quantifies liver iron and cardiac T2-star helps assess myocardial iron in transfusional overload. Liver biopsy is reserved for selected questions about fibrosis, competing diagnoses, or iron distribution when noninvasive testing is insufficient.
Place each clue.
1Liver
MRI estimates iron concentration; fibrosis stage determines prognosis and cancer surveillance.
2Heart
Cardiac T2-star detects myocardial iron that serum ferritin may not predict reliably.
3Pancreas and pituitary
Iron contributes to diabetes, hypogonadism, and other endocrine injury.
4Joints and skin
MCP arthropathy and progressive pigmentation are classic clinical clues.
Remove iron according to the loading mechanism
The same ferritin can require a needle, a chelator, or no iron-removal treatment.
Phlebotomy is first-line for hereditary hemochromatosis with iron overload when hemoglobin and vascular access permit. Induction commonly removes 400 to 500 mL weekly or every 2 weeks, targeting ferritin below 50 micrograms/L, then maintenance usually keeps ferritin around 50 to 100 micrograms/L while avoiding iron deficiency.
Patients with transfusion-dependent anemia cannot routinely tolerate phlebotomy and require individualized chelation with agents such as deferasirox, deferoxamine, or deferiprone plus ferritin trends and organ MRI. Chelation in HFE disease is reserved for unusual situations in which phlebotomy is not feasible. Patients with cirrhosis or advanced fibrosis remain in HCC surveillance even after iron depletion.
Reveal the treatment decision for each branch.
Use serial phlebotomy with hemoglobin and ferritin monitoring.
Red-cell removal safely exports substantial iron.
Use disease-specific iron chelation and MRI-guided monitoring.
Phlebotomy would worsen the underlying anemia.
Treat the underlying disorder and confirm iron loading before iron removal.
Ferritin alone does not justify phlebotomy.
Continue liver care and HCC surveillance after iron depletion.
Cancer risk does not disappear when ferritin normalizes.
Phlebotomy for a full red-cell tank; chelation when transfusions keep filling it.
Key laboratory clue
Choose the compartment that explains the pattern
Localize the defect in bilirubin handling before naming a syndrome.
Which treatment best removes the excess iron?
Key finding. A 52-year-old man has fatigue, second and third MCP arthropathy, diabetes, bronze skin, transferrin saturation of 68 percent, and ferritin of 920 micrograms/L. HFE testing shows C282Y homozygosity.
Answer. Serial therapeutic phlebotomy
Why. An iron-replete patient with HFE-related overload and no anemia is treated by removing iron-containing red cells.
Board rule. HFE overload with usable hemoglobin is a phlebotomy problem.
Stage 1 of 3: Overview
Overview
Hemochromatosis and Iron Overload
Hepcidin is the brake and ferroportin is the exit channel.
Step by step
Trace hepcidin to parenchymal injury
1Sense body ironHFE, transferrin receptors, and hemojuvelin help signal iron sufficiency.
2Produce hepcidinThe liver releases the hormone that restrains systemic iron entry.
3Close ferroportinHepcidin reduces iron export from enterocytes and macrophages.
4Lose the brakePathway defects leave ferroportin active despite adequate stores.
5Injure organsExcess circulating iron loads liver, pancreas, heart, pituitary, joints, and skin.
Clinical takeaway
Why it mattersWhen hepcidin is inappropriately low or ineffective, ferroportin remains active, transferrin becomes highly saturated, non-transferrin-bound iron appears, and parenchymal cells accumulate toxic iron that promotes oxidative injury and fibrosis.
RememberHFE overload with usable hemoglobin is a phlebotomy problem.
Interpret the bilirubin patterns
Five patients test HFE treatment, inflammatory ferritin, non-HFE disease, transfusional chelation, and cancer surveillance after iron depletion.
Cross out the wrong compartment and highlight the clue that localizes bilirubin handling. Each case follows the route step by step.
A 48-year-old man with C282Y homozygosity has transferrin saturation of 64 percent, ferritin of 780 micrograms/L, normal hemoglobin, and no decompensated liver disease.
What is the preferred iron-depletion therapy?
Reason it through
Is the genotype alone the reason to treat?No; the elevated saturation and ferritin establish biochemical loading.
Can he tolerate red-cell removal?Yes; hemoglobin is normal.
Which intervention physically exports iron?Phlebotomy removes iron within hemoglobin.
Treat the phenotype, then use the simplest iron exit.
Is the genotype alone the reason to treat?Can he tolerate red-cell removal?
Is the genotype alone the reason to treat?No; the elevated saturation and ferritin establish biochemical loading.
Can he tolerate red-cell removal?Yes; hemoglobin is normal.
Which intervention physically exports iron?Phlebotomy removes iron within hemoglobin.
A patient with pneumonia and metabolic liver disease has ferritin of 1,100 micrograms/L, transferrin saturation of 24 percent, elevated CRP, and no family history of iron overload.
Which interpretation is most accurate?
Reason it through
What makes ferritin unreliable here?Pneumonia, CRP elevation, and metabolic liver injury.
What happened to transferrin saturation?It is not elevated.
What must precede iron removal?Evidence that excess iron is actually present.
A four-digit ferritin can still be inflammation wearing an iron costume.
What makes ferritin unreliable here?What happened to transferrin saturation?
What makes ferritin unreliable here?Pneumonia, CRP elevation, and metabolic liver injury.
What happened to transferrin saturation?It is not elevated.
What must precede iron removal?Evidence that excess iron is actually present.
A 19-year-old has cardiomyopathy, hypogonadism, liver iron on MRI, transferrin saturation of 88 percent, and negative testing for common HFE variants.
Which diagnostic study should be obtained next?
Reason it through
Why is the age important?Severe organ injury before typical HFE onset suggests juvenile or non-HFE disease.
Does negative HFE testing end the genetic pathway?No; the hepcidin pathway contains other disease genes.
Which evidence confirms clinically important tissue iron loading?Marked saturation plus liver iron and cardiac injury.
Early, severe, and HFE-negative means widen the iron gene map.
Why is the age important?Does negative HFE testing end the genetic pathway?
Why is the age important?Severe organ injury before typical HFE onset suggests juvenile or non-HFE disease.
Does negative HFE testing end the genetic pathway?No; the hepcidin pathway contains other disease genes.
Which evidence confirms clinically important tissue iron loading?Marked saturation plus liver iron and cardiac injury.
A patient with transfusion-dependent beta-thalassemia has chronic anemia, rising ferritin, elevated liver iron by MRI, and reduced cardiac T2-star after years of transfusions.
Which treatment best addresses the iron burden?
Reason it through
How did the iron enter?Repeated donor red-cell transfusions.
Why is phlebotomy unsuitable?The patient is already chronically anemic and transfusion dependent.
What removes iron without removing needed red cells?Iron chelation.
Transfusion-filled iron stores need a chelator, not another blood loss.
How did the iron enter?Why is phlebotomy unsuitable?
How did the iron enter?Repeated donor red-cell transfusions.
Why is phlebotomy unsuitable?The patient is already chronically anemic and transfusion dependent.
What removes iron without removing needed red cells?Iron chelation.
A patient with HFE hemochromatosis and biopsy-proven cirrhosis completes phlebotomy and maintains ferritin at 70 micrograms/L.
Which follow-up remains necessary?
Reason it through
Did treatment remove excess iron?Yes; ferritin is in the maintenance target range.
Did treatment erase established cirrhosis?No; structural liver risk remains.
Which complication requires continued screening?Hepatocellular carcinoma.
Iron can normalize while cirrhosis keeps the cancer clock running.
Did treatment remove excess iron?Did treatment erase established cirrhosis?
Did treatment remove excess iron?Yes; ferritin is in the maintenance target range.
Did treatment erase established cirrhosis?No; structural liver risk remains.
Which complication requires continued screening?Hepatocellular carcinoma.
Rapid review
Three questions to check
Which treatment best removes the excess iron?
Serial therapeutic phlebotomy. An iron-replete patient with HFE-related overload and no anemia is treated by removing iron-containing red cells.
Is the genotype alone the reason to treat?
No; the elevated saturation and ferritin establish biochemical loading.
Resident physician and founding medical reviewer at Bone Wizardry, focused on clinical accuracy, clear diagnostic reasoning, and practical board-oriented teaching across the curriculum.
